HC Wainwright Issues Pessimistic Outlook for KZR Earnings

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Research analysts at HC Wainwright reduced their Q4 2024 earnings estimates for Kezar Life Sciences in a research note issued to investors on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($2.59) per share for the quarter, down from their previous forecast of ($1.70). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($6.30) per share. HC Wainwright also issued estimates for Kezar Life Sciences’ Q1 2025 earnings at ($2.56) EPS, Q2 2025 earnings at ($2.57) EPS, Q3 2025 earnings at ($2.59) EPS, Q4 2025 earnings at ($2.61) EPS and FY2025 earnings at ($10.33) EPS.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($2.78) EPS for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.25.

A number of other equities analysts have also commented on KZR. William Blair reaffirmed a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday, November 13th. Wells Fargo & Company lowered their price target on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 14th.

Kezar Life Sciences Price Performance

NASDAQ:KZR opened at $7.07 on Wednesday. Kezar Life Sciences has a 52 week low of $5.20 and a 52 week high of $11.35. The firm’s 50-day simple moving average is $7.58 and its 200 day simple moving average is $6.77. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05.

Hedge Funds Weigh In On Kezar Life Sciences

Several hedge funds have recently bought and sold shares of KZR. Geode Capital Management LLC boosted its stake in shares of Kezar Life Sciences by 15.0% in the 3rd quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after purchasing an additional 81,678 shares in the last quarter. XTX Topco Ltd boosted its position in Kezar Life Sciences by 256.1% during the 3rd quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after buying an additional 37,504 shares during the period. Ikarian Capital LLC boosted its position in Kezar Life Sciences by 23.0% during the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after buying an additional 200,000 shares during the period. Stonepine Capital Management LLC boosted its position in Kezar Life Sciences by 42.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock worth $1,153,000 after buying an additional 440,853 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Kezar Life Sciences during the 2nd quarter worth approximately $63,000. 67.90% of the stock is owned by institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.